25 XP   0   0   10

Travere Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Travere together

PenkeI guess you are interested in Travere Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Travere Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Travere Therapeutics Inc

I send you an email if I find something interesting about Travere Therapeutics Inc.

Quick analysis of Travere (30 sec.)










What can you expect buying and holding a share of Travere? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$2.63
Expected worth in 1 year
$4.69
How sure are you?
37.5%

+ What do you gain per year?

Total Gains per Share
$2.06
Return On Investment
34.4%

For what price can you sell your share?

Current Price per Share
$5.99
Expected price per share
$5.25 - $8.99
How sure are you?
50%

1. Valuation of Travere (5 min.)




Live pricePrice per Share (EOD)

$5.99

Intrinsic Value Per Share

$-30.34 - $20.47

Total Value Per Share

$-27.72 - $23.10

2. Growth of Travere (5 min.)




Is Travere growing?

Current yearPrevious yearGrowGrow %
How rich?$200.8m$127m$69.4m35.3%

How much money is Travere making?

Current yearPrevious yearGrowGrow %
Making money-$27.8m-$69.6m$41.7m150.0%
Net Profit Margin-22.2%-132.1%--

How much money comes from the company's main activities?

3. Financial Health of Travere (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#255 / 1019

Most Revenue
#156 / 1019

Most Profit
#769 / 1019

Most Efficient
#502 / 1019

What can you expect buying and holding a share of Travere? (5 min.)

Welcome investor! Travere's management wants to use your money to grow the business. In return you get a share of Travere.

What can you expect buying and holding a share of Travere?

First you should know what it really means to hold a share of Travere. And how you can make/lose money.

Speculation

The Price per Share of Travere is $5.99. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Travere.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Travere, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.63. Based on the TTM, the Book Value Change Per Share is $0.52 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.85 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Travere.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.18-19.7%-0.37-6.1%-0.91-15.3%-0.58-9.7%-0.36-6.0%
Usd Book Value Change Per Share-1.04-17.4%0.528.6%-0.85-14.2%-0.08-1.3%0.071.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.010.2%
Usd Total Gains Per Share-1.04-17.4%0.528.6%-0.85-14.2%-0.08-1.3%0.081.4%
Usd Price Per Share8.99-13.95-23.92-19.78-20.10-
Price to Earnings Ratio-1.91--2.29--6.53-9.89--5.87-
Price-to-Total Gains Ratio-8.64--2.21--29.46--41.00-124.57-
Price to Book Ratio3.42-6.24-19.29-8.44-24.26-
Price-to-Total Gains Ratio-8.64--2.21--29.46--41.00-124.57-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.99
Number of shares166
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.52-0.08
Usd Total Gains Per Share0.52-0.08
Gains per Quarter (166 shares)85.60-12.92
Gains per Year (166 shares)342.42-51.67
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
103423320-52-62
206856740-103-114
30102710160-155-166
40137013580-207-218
50171217000-258-270
60205420420-310-322
70239723840-362-374
80273927260-413-426
90308230680-465-478
100342434100-517-530

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%2.018.00.010.0%6.034.00.015.0%6.048.00.011.1%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%14.026.00.035.0%14.038.02.025.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%1.00.053.01.9%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%15.025.00.037.5%15.037.02.027.8%

Fundamentals of Travere

About Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-04-12 20:46:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Travere Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Travere earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Travere to the Biotechnology industry mean.
  • A Net Profit Margin of -200.1% means that $-2.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Travere Therapeutics Inc:

  • The MRQ is -200.1%. The company is making a huge loss. -2
  • The TTM is -22.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-200.1%TTM-22.2%-177.9%
TTM-22.2%YOY-132.1%+109.9%
TTM-22.2%5Y-80.8%+58.7%
5Y-80.8%10Y-6,377.4%+6,296.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-200.1%-197.2%-2.9%
TTM-22.2%-210.4%+188.2%
YOY-132.1%-279.3%+147.2%
5Y-80.8%-436.8%+356.0%
10Y-6,377.4%-599.3%-5,778.1%
1.1.2. Return on Assets

Shows how efficient Travere is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Travere to the Biotechnology industry mean.
  • -11.4% Return on Assets means that Travere generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Travere Therapeutics Inc:

  • The MRQ is -11.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.4%TTM-3.9%-7.5%
TTM-3.9%YOY-9.3%+5.4%
TTM-3.9%5Y-6.3%+2.4%
5Y-6.3%10Y-6.1%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.4%-13.6%+2.2%
TTM-3.9%-12.9%+9.0%
YOY-9.3%-11.9%+2.6%
5Y-6.3%-14.2%+7.9%
10Y-6.1%-16.2%+10.1%
1.1.3. Return on Equity

Shows how efficient Travere is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Travere to the Biotechnology industry mean.
  • -44.9% Return on Equity means Travere generated $-0.45 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Travere Therapeutics Inc:

  • The MRQ is -44.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -27.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-44.9%TTM-27.5%-17.4%
TTM-27.5%YOY-75.5%+48.0%
TTM-27.5%5Y-29.9%+2.3%
5Y-29.9%10Y4.3%-34.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-44.9%-17.0%-27.9%
TTM-27.5%-16.1%-11.4%
YOY-75.5%-15.4%-60.1%
5Y-29.9%-20.0%-9.9%
10Y4.3%-21.1%+25.4%

1.2. Operating Efficiency of Travere Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Travere is operating .

  • Measures how much profit Travere makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Travere to the Biotechnology industry mean.
  • An Operating Margin of -183.8% means the company generated $-1.84  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Travere Therapeutics Inc:

  • The MRQ is -183.8%. The company is operating very inefficient. -2
  • The TTM is -178.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-183.8%TTM-178.9%-4.9%
TTM-178.9%YOY-118.6%-60.3%
TTM-178.9%5Y-91.7%-87.2%
5Y-91.7%10Y3,195.8%-3,287.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-183.8%-286.1%+102.3%
TTM-178.9%-224.4%+45.5%
YOY-118.6%-288.4%+169.8%
5Y-91.7%-475.2%+383.5%
10Y3,195.8%-624.7%+3,820.5%
1.2.2. Operating Ratio

Measures how efficient Travere is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.84 means that the operating costs are $2.84 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Travere Therapeutics Inc:

  • The MRQ is 2.838. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.804. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.838TTM2.804+0.035
TTM2.804YOY2.186+0.618
TTM2.8045Y1.910+0.893
5Y1.91010Y16.964-15.054
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8382.997-0.159
TTM2.8043.247-0.443
YOY2.1863.766-1.580
5Y1.9105.675-3.765
10Y16.9647.857+9.107

1.3. Liquidity of Travere Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Travere is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.47 means the company has $3.47 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Travere Therapeutics Inc:

  • The MRQ is 3.467. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.253. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.467TTM4.253-0.786
TTM4.253YOY4.375-0.122
TTM4.2535Y4.999-0.746
5Y4.99910Y4.056+0.943
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4673.930-0.463
TTM4.2534.251+0.002
YOY4.3755.436-1.061
5Y4.9996.045-1.046
10Y4.0566.363-2.307
1.3.2. Quick Ratio

Measures if Travere is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Travere to the Biotechnology industry mean.
  • A Quick Ratio of 6.16 means the company can pay off $6.16 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Travere Therapeutics Inc:

  • The MRQ is 6.164. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.183. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.164TTM7.183-1.019
TTM7.183YOY7.085+0.098
TTM7.1835Y8.245-1.062
5Y8.24510Y6.510+1.735
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1643.629+2.535
TTM7.1834.065+3.118
YOY7.0855.397+1.688
5Y8.2455.993+2.252
10Y6.5106.277+0.233

1.4. Solvency of Travere Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Travere assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Travere to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.75 means that Travere assets are financed with 74.5% credit (debt) and the remaining percentage (100% - 74.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Travere Therapeutics Inc:

  • The MRQ is 0.745. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.754. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.745TTM0.754-0.009
TTM0.754YOY0.836-0.082
TTM0.7545Y0.669+0.085
5Y0.66910Y0.635+0.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7450.332+0.413
TTM0.7540.334+0.420
YOY0.8360.268+0.568
5Y0.6690.366+0.303
10Y0.6350.390+0.245
1.4.2. Debt to Equity Ratio

Measures if Travere is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Travere to the Biotechnology industry mean.
  • A Debt to Equity ratio of 292.9% means that company has $2.93 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Travere Therapeutics Inc:

  • The MRQ is 2.929. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.375. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.929TTM3.375-0.447
TTM3.375YOY6.966-3.591
TTM3.3755Y2.928+0.447
5Y2.92810Y5.439-2.511
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9290.381+2.548
TTM3.3750.390+2.985
YOY6.9660.334+6.632
5Y2.9280.434+2.494
10Y5.4390.466+4.973

2. Market Valuation of Travere Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Travere generates.

  • Above 15 is considered overpriced but always compare Travere to the Biotechnology industry mean.
  • A PE ratio of -1.91 means the investor is paying $-1.91 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Travere Therapeutics Inc:

  • The EOD is -1.270. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.906. Based on the earnings, the company is expensive. -2
  • The TTM is -2.286. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.270MRQ-1.906+0.636
MRQ-1.906TTM-2.286+0.380
TTM-2.286YOY-6.535+4.249
TTM-2.2865Y9.891-12.177
5Y9.89110Y-5.875+15.766
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.270-2.315+1.045
MRQ-1.906-2.560+0.654
TTM-2.286-2.664+0.378
YOY-6.535-4.122-2.413
5Y9.891-6.258+16.149
10Y-5.875-6.108+0.233
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Travere Therapeutics Inc:

  • The EOD is -1.507. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.261. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.213. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.507MRQ-2.261+0.755
MRQ-2.261TTM-3.213+0.951
TTM-3.213YOY-8.596+5.383
TTM-3.2135Y-100.635+97.422
5Y-100.63510Y-48.656-51.979
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.507-3.067+1.560
MRQ-2.261-3.251+0.990
TTM-3.213-3.545+0.332
YOY-8.596-5.595-3.001
5Y-100.635-8.315-92.320
10Y-48.656-8.708-39.948
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Travere is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.42 means the investor is paying $3.42 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Travere Therapeutics Inc:

  • The EOD is 2.281. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.424. Based on the equity, the company is fair priced.
  • The TTM is 6.236. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD2.281MRQ3.424-1.142
MRQ3.424TTM6.236-2.813
TTM6.236YOY19.290-13.054
TTM6.2365Y8.440-2.204
5Y8.44010Y24.257-15.817
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.2811.905+0.376
MRQ3.4242.111+1.313
TTM6.2362.095+4.141
YOY19.2902.836+16.454
5Y8.4403.443+4.997
10Y24.2573.794+20.463
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Travere Therapeutics Inc.

3.1. Institutions holding Travere Therapeutics Inc

Institutions are holding 115.179% of the shares of Travere Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc10.40480.001879178602846553.7292
2023-12-31Armistice Capital, LLC9.70320.90627384000-116000-1.5467
2023-12-31Deep Track Capital, LP9.68482.2127737000000
2023-12-31Vanguard Group Inc7.24740.0011551514384768518.1616
2023-12-31State Street Corporation7.03340.0023535234595708821.7755
2023-12-31Macquarie Group Ltd6.23770.04934746776749171.6036
2023-12-31Morgan Stanley - Brokerage Accounts5.43540.00334136290189595384.628
2023-12-31Renaissance Technologies Corp4.04870.04293081014108689254.5048
2023-12-31Goldman Sachs Group Inc3.91790.00242981496146940997.1775
2023-12-31Rock Springs Capital Management LP3.64190.6134277144696370453.3098
2023-09-30VR Adviser, LLC3.44772.4692262367726236770
2023-12-31Deutsche Bank AG3.15480.01124007672092311678.3175
2023-12-31Pictet Asset Manangement SA3.11030.0235236687822633810.5739
2023-12-31Kynam Capital Management, LP2.62821.99220000001042498108.8768
2023-09-30Jacobs Levy Equity Management, Inc.2.19690.088516717701469709.6386
2023-12-31Bank of America Corp2.13070.0015162146740624133.4293
2023-12-31Geode Capital Management, LLC1.99970.00141521730810865.6285
2023-12-31Finepoint Capital LP1.88614.0709143532153950060.2241
2023-12-31Millennium Management LLC1.70120.0051294586-2058795-61.3946
2023-12-31Farallon Capital Management, L.L.C.1.43760.04881094000822483302.9214
Total 91.048412.547269286566+13386612+19.3%

3.2. Funds holding Travere Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29SPDR® S&P Biotech ETF5.30050.38514033631753601.9039
2023-12-31Macquarie US Small Cap Core Equity4.74090.4339360777100
2024-01-31Delaware Small Cap Core I4.68480.44993565035-42736-1.1846
2024-02-29Aviva Investors GlConvtAbsRet I USD Acc3.191702428812-59683-2.3984
2024-02-29Vanguard Total Stock Mkt Idx Inv3.10050.00122359420-24100-1.0111
2024-02-29iShares Russell 2000 ETF2.30660.02131755251-287-0.0163
2023-10-13Pictet Biopharmaceutical Mother1.43180.5198108960030846539.4893
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.31230.0074998622115331.1684
2023-12-31Fidelity Small Cap Index0.95320.0257725345106611.4917
2023-12-31HBM Healthcare Investments AG Ord0.95170.326172419600
2024-01-31Emerald Growth A0.91750.6885698168361459107.3506
2024-02-29iShares Russell 2000 Growth ETF0.78810.0399599744138042.3559
2024-02-29BlackRock Advantage Small Cap Core Instl0.73350.1202558193-33733-5.6989
2024-02-29iShares Biotechnology ETF0.70990.0537540256-2430-0.4478
2024-01-31TIAA-CREF Quant Small-Cap Equity Instl0.70480.159953635023092075.6049
2023-12-31Vanguard Strategic Equity Inv0.66960.058850953816656748.5659
2023-12-31Vanguard Explorer Inv0.62730.0201477361295612162.6485
2024-02-29Principal SmallCap Growth I Instl0.61860.14174707364280.091
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.57250.007943568572001.6803
2024-01-31Fidelity Extended Market Index0.50150.009538159641191.0912
Total 34.81733.470626495310+1323159+5.0%

3.3. Insider Transactions

Insiders are holding 1.015% of the shares of Travere Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-01Eric M DubeSELL191228.7
2024-02-01Peter HeermaSELL41958.53
2024-02-01Sandra CalvinSELL28208.53
2024-02-01William E RoteSELL47648.71
2024-02-01Christopher R ClineSELL38188.53
2024-01-23Sandra CalvinSELL9109.07
2024-01-23Peter HeermaSELL15599.07
2024-01-23Eric M DubeSELL78738.96
2024-01-23Elizabeth E ReedSELL20628.96
2024-01-23Christopher R ClineSELL8539.07
2024-01-03Jula InrigSELL20699.48
2023-10-03Peter HeermaSELL30918.25
2023-09-05Christopher R ClineSELL45714.71
2023-09-05Eric M DubeSELL445514.71
2023-09-05William E RoteSELL181514.71
2023-05-10Christopher R ClineSELL45516.59
2023-05-10Elizabeth E ReedSELL82516.59
2023-05-10Sandra CalvinSELL43616.59
2023-04-11Christopher R ClineSELL4721.49

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Travere Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.0410.516-302%-0.852-18%-0.078-93%0.072-1552%
Book Value Per Share--2.6262.577+2%1.670+57%3.078-15%3.016-13%
Current Ratio--3.4674.253-18%4.375-21%4.999-31%4.056-15%
Debt To Asset Ratio--0.7450.754-1%0.836-11%0.669+11%0.635+17%
Debt To Equity Ratio--2.9293.375-13%6.966-58%2.928+0%5.439-46%
Dividend Per Share----0%-0%-0%0.010-100%
Eps---1.179-0.366-69%-0.915-22%-0.582-51%-0.358-70%
Free Cash Flow Per Share---0.994-1.057+6%-0.706-29%-0.533-46%-0.307-69%
Free Cash Flow To Equity Per Share---0.992-0.338-66%-0.320-68%-0.078-92%0.062-1713%
Gross Profit Margin--1.1201.030+9%1.000+12%1.006+11%1.003+12%
Intrinsic Value_10Y_max--20.472--------
Intrinsic Value_10Y_min---30.343--------
Intrinsic Value_1Y_max---0.754--------
Intrinsic Value_1Y_min---2.626--------
Intrinsic Value_3Y_max---0.127--------
Intrinsic Value_3Y_min---8.296--------
Intrinsic Value_5Y_max--3.077--------
Intrinsic Value_5Y_min---14.367--------
Market Cap455829991.040-51%687506294.4001062501614.705-35%1820085778.080-62%1505204499.117-54%1529624967.591-55%
Net Profit Margin---2.001-0.222-89%-1.321-34%-0.808-60%-63.774+3087%
Operating Margin---1.838-1.789-3%-1.186-35%-0.917-50%31.958-106%
Operating Ratio--2.8382.804+1%2.186+30%1.910+49%16.964-83%
Pb Ratio2.281-50%3.4246.236-45%19.290-82%8.440-59%24.257-86%
Pe Ratio-1.270+33%-1.906-2.286+20%-6.535+243%9.891-119%-5.875+208%
Price Per Share5.990-50%8.99013.945-36%23.918-62%19.776-55%20.099-55%
Price To Free Cash Flow Ratio-1.507+33%-2.261-3.213+42%-8.596+280%-100.635+4350%-48.656+2052%
Price To Total Gains Ratio-5.757+33%-8.640-2.211-74%-29.465+241%-41.002+375%124.566-107%
Quick Ratio--6.1647.183-14%7.085-13%8.245-25%6.510-5%
Return On Assets---0.114-0.039-66%-0.093-19%-0.063-45%-0.061-46%
Return On Equity---0.449-0.275-39%-0.755+68%-0.299-34%0.043-1150%
Total Gains Per Share---1.0410.516-302%-0.852-18%-0.078-93%0.081-1379%
Usd Book Value--200810000.000196550250.000+2%127095250.000+58%234301400.000-14%229569026.800-13%
Usd Book Value Change Per Share---1.0410.516-302%-0.852-18%-0.078-93%0.072-1552%
Usd Book Value Per Share--2.6262.577+2%1.670+57%3.078-15%3.016-13%
Usd Dividend Per Share----0%-0%-0%0.010-100%
Usd Eps---1.179-0.366-69%-0.915-22%-0.582-51%-0.358-70%
Usd Free Cash Flow---76003000.000-80570000.000+6%-53712000.000-29%-40621900.000-47%-23365522.025-69%
Usd Free Cash Flow Per Share---0.994-1.057+6%-0.706-29%-0.533-46%-0.307-69%
Usd Free Cash Flow To Equity Per Share---0.992-0.338-66%-0.320-68%-0.078-92%0.062-1713%
Usd Market Cap455829991.040-51%687506294.4001062501614.705-35%1820085778.080-62%1505204499.117-54%1529624967.591-55%
Usd Price Per Share5.990-50%8.99013.945-36%23.918-62%19.776-55%20.099-55%
Usd Profit---90173000.000-27849750.000-69%-69620500.000-23%-44291500.000-51%-27246071.825-70%
Usd Revenue--45059000.00049711000.000-9%53004500.000-15%50600500.000-11%39821950.125+13%
Usd Total Gains Per Share---1.0410.516-302%-0.852-18%-0.078-93%0.081-1379%
 EOD+3 -5MRQTTM+11 -23YOY+10 -245Y+5 -2910Y+7 -29

4.2. Fundamental Score

Let's check the fundamental score of Travere Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.270
Price to Book Ratio (EOD)Between0-12.281
Net Profit Margin (MRQ)Greater than0-2.001
Operating Margin (MRQ)Greater than0-1.838
Quick Ratio (MRQ)Greater than16.164
Current Ratio (MRQ)Greater than13.467
Debt to Asset Ratio (MRQ)Less than10.745
Debt to Equity Ratio (MRQ)Less than12.929
Return on Equity (MRQ)Greater than0.15-0.449
Return on Assets (MRQ)Greater than0.05-0.114
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Travere Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.683
Ma 20Greater thanMa 507.085
Ma 50Greater thanMa 1007.695
Ma 100Greater thanMa 2008.074
OpenGreater thanClose6.240
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets788,913
Total Liabilities588,103
Total Stockholder Equity200,810
 As reported
Total Liabilities 588,103
Total Stockholder Equity+ 200,810
Total Assets = 788,913

Assets

Total Assets788,913
Total Current Assets616,775
Long-term Assets172,138
Total Current Assets
Cash And Cash Equivalents 58,176
Short-term Investments 508,675
Net Receivables 21,179
Inventory 9,410
Other Current Assets 19,335
Total Current Assets  (as reported)616,775
Total Current Assets  (calculated)616,775
+/-0
Long-term Assets
Property Plant Equipment 25,540
Goodwill 800
Intangible Assets 103,690
Long-term Assets Other 42,108
Long-term Assets  (as reported)172,138
Long-term Assets  (calculated)172,138
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities177,908
Long-term Liabilities410,195
Total Stockholder Equity200,810
Total Current Liabilities
Short-term Debt 4,909
Accounts payable 41,675
Other Current Liabilities 124,228
Total Current Liabilities  (as reported)177,908
Total Current Liabilities  (calculated)170,812
+/- 7,096
Long-term Liabilities
Long term Debt 377,263
Capital Lease Obligations Min Short Term Debt22,612
Long-term Liabilities Other 8,485
Long-term Liabilities  (as reported)410,195
Long-term Liabilities  (calculated)408,360
+/- 1,835
Total Stockholder Equity
Common Stock7
Retained Earnings -1,125,622
Accumulated Other Comprehensive Income -1,456
Other Stockholders Equity 1,327,881
Total Stockholder Equity (as reported)200,810
Total Stockholder Equity (calculated)200,810
+/-0
Other
Capital Stock7
Cash and Short Term Investments 566,851
Common Stock Shares Outstanding 76,475
Current Deferred Revenue7,096
Liabilities and Stockholders Equity 788,913
Net Debt 346,608
Net Invested Capital 578,073
Net Working Capital 438,867
Property Plant and Equipment Gross 32,983
Short Long Term Debt Total 404,784



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-30
> Total Assets 
0
5
4
4
4
4
4
4
4
4
4
4,951
4,951
21,365
20,499
94,049
155,535
145,932
135,471
415,988
425,140
511,630
512,400
507,100
533,971
532,420
525,282
510,381
507,130
520,510
520,346
500,794
491,144
716,186
709,160
667,668
647,574
613,816
604,800
573,063
678,694
692,220
607,439
764,045
746,766
775,075
776,633
828,405
779,494
726,215
672,585
808,231
736,429
832,850
788,913
788,913832,850736,429808,231672,585726,215779,494828,405776,633775,075746,766764,045607,439692,220678,694573,063604,800613,816647,574667,668709,160716,186491,144500,794520,346520,510507,130510,381525,282532,420533,971507,100512,400511,630425,140415,988135,471145,932155,53594,04920,49921,3654,9514,95144444444450
   > Total Current Assets 
0
5
4
4
4
4
4
4
4
4
4
2,638
2,638
16,848
7,501
6,442
53,397
45,445
37,334
233,543
244,737
299,954
301,932
297,739
300,157
342,590
332,352
322,398
319,658
325,339
325,807
286,803
278,917
502,989
495,678
475,513
457,015
439,718
429,064
406,630
505,562
497,682
410,407
565,040
549,798
579,079
582,827
631,093
586,777
534,842
486,437
604,904
542,055
686,230
616,775
616,775686,230542,055604,904486,437534,842586,777631,093582,827579,079549,798565,040410,407497,682505,562406,630429,064439,718457,015475,513495,678502,989278,917286,803325,807325,339319,658322,398332,352342,590300,157297,739301,932299,954244,737233,54337,33445,44553,3976,4427,50116,8482,6382,63844444444450
       Cash And Cash Equivalents 
0
5
4
4
4
4
4
4
4
4
4
2,503
2,503
13,410
5,997
3,695
39,880
25,862
18,204
120,175
127,746
140,596
37,805
23,262
21,155
23,895
41,002
41,871
89,265
98,991
99,394
61,117
89,305
154,820
102,873
69,838
75,657
65,188
62,436
67,019
237,170
200,481
84,772
148,232
83,288
150,327
165,753
256,572
179,759
151,337
61,688
161,376
70,874
144,244
58,176
58,176144,24470,874161,37661,688151,337179,759256,572165,753150,32783,288148,23284,772200,481237,17067,01962,43665,18875,65769,838102,873154,82089,30561,11799,39498,99189,26541,87141,00223,89521,15523,26237,805140,596127,746120,17518,20425,86239,8803,6955,99713,4102,5032,50344444444450
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
2,957
133
1,345
3,564
11,930
9,556
6,160
5,862
94,681
191,799
199,083
200,359
250,408
214,871
206,290
206,716
204,882
201,236
202,939
166,381
323,993
368,668
377,808
350,243
341,835
336,088
289,441
220,206
255,786
276,817
372,639
439,502
400,857
387,129
346,818
373,414
354,989
388,557
400,137
420,463
490,399
508,675
508,675490,399420,463400,137388,557354,989373,414346,818387,129400,857439,502372,639276,817255,786220,206289,441336,088341,835350,243377,808368,668323,993166,381202,939201,236204,882206,716206,290214,871250,408200,359199,083191,79994,6815,8626,1609,55611,9303,5641,3451332,9570000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29
7,565
4,677
7,959
8,163
11,467
60,025
59,307
60,573
64,066
61,481
65,359
62,600
13,321
14,543
13,872
12,981
12,324
13,450
14,490
12,713
15,451
16,781
18,048
38,268
34,186
28,640
33,067
30,239
12,260
13,775
16,161
14,675
16,689
12,670
16,646
21,537
20,397
14,570
21,179
21,17914,57020,39721,53716,64612,67016,68914,67516,16113,77512,26030,23933,06728,64034,18638,26818,04816,78115,45112,71314,49013,45012,32412,98113,87214,54313,32162,60065,35961,48164,06660,57359,30760,02511,4678,1637,9594,6777,56529000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
134
481
1,371
1,024
1,891
2,292
813
97,327
97,657
2,002
10,485
11,591
11,864
3,553
8,294
6,886
5,987
2,605
5,954
4,624
5,519
5,597
4,028
9,583
10,614
10,650
6,410
5,309
7,714
5,516
8,143
6,747
7,339
7,504
6,471
6,507
9,283
8,549
12,624
15,142
11,556
16,244
19,335
19,33516,24411,55615,14212,6248,5499,2836,5076,4717,5047,3396,7478,1435,5167,7145,3096,41010,65010,6149,5834,0285,5975,5194,6245,9542,6055,9876,8868,2943,55311,86411,59110,4852,00297,65797,3278132,2921,8911,0241,371481134000000000000
   > Long-term Assets 
0
0
0
0
0
4
0
0
0
0
0
2,313
2,313
4,517
12,998
87,606
102,138
100,487
98,137
182,445
180,403
211,676
210,468
209,361
233,814
189,830
192,930
187,983
187,472
195,171
194,539
213,991
212,227
213,197
213,482
192,155
190,559
174,098
175,736
166,433
173,132
194,538
197,032
199,005
196,968
195,996
193,806
197,312
192,681
191,337
186,148
203,327
194,338
146,620
172,138
172,138146,620194,338203,327186,148191,337192,681197,312193,806195,996196,968199,005197,032194,538173,132166,433175,736174,098190,559192,155213,482213,197212,227213,991194,539195,171187,472187,983192,930189,830233,814209,361210,468211,676180,403182,44598,137100,487102,13887,60612,9984,5172,3132,31300000400000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
28
28
38
127
280
511
633
671
619
509
478
428
417
381
382
2,587
2,428
2,540
2,717
3,230
3,042
3,455
3,323
3,146
2,995
3,015
2,910
2,891
2,617
2,930
5,696
9,418
11,697
11,720
11,513
34,302
33,159
31,990
30,810
30,049
29,416
28,129
26,802
25,540
25,54026,80228,12929,41630,04930,81031,99033,15934,30211,51311,72011,6979,4185,6962,9302,6172,8912,9103,0152,9953,1463,3233,4553,0423,2302,7172,5402,4282,58738238141742847850961967163351128012738282800000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,036
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
936
900
900
900
900
900
800
800
8008009009009009009009369369369369369369369369369369369369369369369369369369369369369369369369369369369369369369369361,036000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
2,147
2,147
2,051
12,586
84,484
98,034
96,220
94,266
169,835
168,251
162,997
161,536
160,260
184,432
183,298
182,043
180,958
180,368
179,569
184,817
188,556
187,485
186,545
186,691
159,753
158,906
157,799
157,200
156,077
155,371
154,217
153,189
151,342
149,951
148,676
148,435
152,385
148,984
148,533
145,038
161,983
153,520
106,903
103,690
103,690106,903153,520161,983145,038148,533148,984152,385148,435148,676149,951151,342153,189154,217155,371156,077157,200157,799158,906159,753186,691186,545187,485188,556184,817179,569180,368180,958182,043183,298184,432160,260161,536162,997168,251169,83594,26696,22098,03484,48412,5862,0512,1472,14700000000000
       Other Assets 
0
0
0
0
0
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,995
7,389
7,814
9,992
9,945
34,871
11,069
10,832
36
36
36
0
36
0
0
0036036363610,83211,06934,8719,9459,9927,8147,3896,9950000000000000000000000000000000000400000
> Total Liabilities 
0
57
64
64
65
65
66
67
67
68
69
8,172
8,172
27,169
38,811
129,441
154,468
156,120
172,722
247,421
274,359
220,618
212,429
187,868
219,599
224,825
217,515
209,446
211,301
215,990
227,212
201,319
203,155
397,121
390,907
381,957
370,485
367,859
383,604
347,315
360,049
390,807
396,226
401,356
414,463
467,705
474,521
620,264
622,781
625,539
629,734
619,091
619,944
553,084
588,103
588,103553,084619,944619,091629,734625,539622,781620,264474,521467,705414,463401,356396,226390,807360,049347,315383,604367,859370,485381,957390,907397,121203,155201,319227,212215,990211,301209,446217,515224,825219,599187,868212,429220,618274,359247,421172,722156,120154,468129,44138,81127,1698,1728,172696867676665656464570
   > Total Current Liabilities 
0
57
64
64
65
1
66
67
67
68
69
1,215
1,215
27,169
35,210
113,447
47,985
49,135
107,539
102,165
172,382
101,947
85,798
66,617
80,068
85,994
83,262
76,555
79,626
83,904
85,668
56,525
103,497
99,872
104,621
104,075
90,587
88,017
95,449
68,091
69,933
75,426
92,660
85,013
96,977
113,163
124,088
119,473
124,492
131,032
142,163
130,645
135,711
139,433
177,908
177,908139,433135,711130,645142,163131,032124,492119,473124,088113,16396,97785,01392,66075,42669,93368,09195,44988,01790,587104,075104,62199,872103,49756,52585,66883,90479,62676,55583,26285,99480,06866,61785,798101,947172,382102,165107,53949,13547,985113,44735,21027,1691,2151,21569686767661656464570
       Short-term Debt 
0
7
25
25
25
25
25
25
25
25
25
0
0
0
-2,596,485
31,283
0
0
40,485
0
41,125
0
-508
0
0
0
26,883
0
0
0
0
0
45,401
22,377
22,457
22,537
0
0
0
0
0
0
492,156
590,715
220,861
63,308
3,908
4,014
4,123
4,233
4,433
4,545
4,663
4,782
4,909
4,9094,7824,6634,5454,4334,2334,1234,0143,90863,308220,861590,715492,15600000022,53722,45722,37745,4010000026,883000-508041,125040,4850031,283-2,596,48500025252525252525252570
       Accounts payable 
0
1
0
1
1
1
1
1
1
1
1
0
485
1,722
3,554
5,711
10,625
11,285
7,124
5,913
4,778
4,893
7,639
4,647
6,285
3,066
7,522
4,671
9,076
7,370
18,938
9,423
7,847
9,314
6,954
7,627
12,519
13,832
26,614
9,966
10,198
9,431
12,133
15,008
8,343
5,830
15,144
18,434
11,848
14,010
17,290
16,727
19,915
24,736
41,675
41,67524,73619,91516,72717,29014,01011,84818,43415,1445,8308,34315,00812,1339,43110,1989,96626,61413,83212,5197,6276,9549,3147,8479,42318,9387,3709,0764,6717,5223,0666,2854,6477,6394,8934,7785,9137,12411,28510,6255,7113,5541,722485011111111010
       Other Current Liabilities 
0
57
0
38
39
-1
40
41
42
42
43
0
730
25,448
27,242
71,651
37,360
37,850
-81,222
96,252
96,460
97,054
54,339
61,970
73,783
82,928
42,432
71,884
70,550
76,534
66,730
47,102
14,979
24,833
25,515
27,292
78,068
74,185
68,835
58,125
59,735
65,995
80,527
70,005
88,634
27,956
88,768
82,796
96,018
101,406
108,464
98,398
100,889
100,956
124,228
124,228100,956100,88998,398108,464101,40696,01882,79688,76827,95688,63470,00580,52765,99559,73558,12568,83574,18578,06827,29225,51524,83314,97947,10266,73076,53470,55071,88442,43282,92873,78361,97054,33997,05496,46096,252-81,22237,85037,36071,65127,24225,44873004342424140-139380570
   > Long-term Liabilities 
0
0
0
26
0
1
26
26
26
26
26
6,957
6,957
1,722
3,601
15,994
106,484
106,985
65,183
145,256
101,977
118,671
126,631
121,251
139,531
138,831
134,253
132,891
131,675
132,086
141,544
144,794
99,658
297,249
286,286
277,882
279,898
279,842
288,155
279,224
290,116
315,381
303,566
316,343
317,486
354,542
350,433
500,791
498,289
494,507
487,571
488,446
484,233
413,651
410,195
410,195413,651484,233488,446487,571494,507498,289500,791350,433354,542317,486316,343303,566315,381290,116279,224288,155279,842279,898277,882286,286297,24999,658144,794141,544132,086131,675132,891134,253138,831139,531121,251126,631118,671101,977145,25665,183106,985106,48415,9943,6011,7226,9576,95726262626261026000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
215,339
218,076
220,861
223,696
0
374,333
374,690
375,117
0
375,974
376,403
0
0
00376,403375,9740375,117374,690374,3330223,696220,861218,076215,339000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
73,218
74,808
59,891
67,061
63,709
130,846
92,355
96,019
94,240
91,123
84,516
0
82,724
0
0
0082,724084,51691,12394,24096,01992,355130,84663,70967,06159,89174,80873,2180000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-60
0
-61
-62
-63
-64
-64
-65
0
-3,222
-5,804
-18,312
-35,392
1,067
-10,188
-37,251
168,567
150,781
291,012
299,971
319,232
314,372
307,595
307,767
300,935
295,829
304,520
293,134
299,475
287,989
319,065
318,253
285,711
277,089
245,957
221,196
225,748
318,645
301,413
211,213
362,689
332,303
307,370
302,112
208,141
156,713
100,676
42,851
189,140
116,485
279,766
200,810
200,810279,766116,485189,14042,851100,676156,713208,141302,112307,370332,303362,689211,213301,413318,645225,748221,196245,957277,089285,711318,253319,065287,989299,475293,134304,520295,829300,935307,767307,595314,372319,232299,971291,012150,781168,567-37,251-10,1881,067-35,392-18,312-5,804-3,2220-65-64-64-63-62-610-60000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
1
2
2
2
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
5
5
5
6
6
6
6
6
6
6
6
7
7
7
7
7777666666665554444444444444444444333332221000000000000
   Retained Earnings Total Equity00-1,186,184-1,100,554-1,014,223-948,400-878,744-811,712-765,966-714,393-678,754-639,742-585,875000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
-155
-110
512
409
3,744
4,286
1,087
760
-102
-682
-162
21
-304
-490
-421
-576
-595
-1,015
-1,529
-1,152
-1,083
-1,529
57
781
1,172
726
-1,500
1,399
354
-902
-262
-641
-525
-562
-1,695
-1,082
303
-2,907
-2,176
-3,855
-3,653
-1,456
-1,456-3,653-3,855-2,176-2,907303-1,082-1,695-562-525-641-262-9023541,399-1,5007261,17278157-1,529-1,083-1,152-1,529-1,015-595-576-421-490-30421-162-682-1027601,0874,2863,744409512-110-1550000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
797,985
1,002,687
1,011,692
1,022,282
1,068,634
1,021,542
1,036,533
1,048,767
1,059,975
1,291,863
1,306,517
0
0
001,306,5171,291,8631,059,9751,048,7671,036,5331,021,5421,068,6341,022,2821,011,6921,002,687797,985000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
55
0
61
125
67
70
73
76
79
82
0
35,132
48,650
49,232
102,155
130,234
135,200
137,636
310,211
318,280
353,794
365,802
373,327
381,687
412,348
421,309
430,366
438,644
465,148
471,800
486,717
497,183
582,706
589,795
596,644
625,999
630,966
636,910
642,880
758,945
765,307
797,985
1,002,687
1,011,692
1,022,282
1,068,634
1,021,542
1,036,533
1,048,767
1,059,975
1,291,863
1,306,517
1,318,861
1,327,881
1,327,8811,318,8611,306,5171,291,8631,059,9751,048,7671,036,5331,021,5421,068,6341,022,2821,011,6921,002,687797,985765,307758,945642,880636,910630,966625,999596,644589,795582,706497,183486,717471,800465,148438,644430,366421,309412,348381,687373,327365,802353,794318,280310,211137,636135,200130,234102,15549,23248,65035,1320827976737067125610550



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue145,238
Cost of Revenue-56,382
Gross Profit88,85688,856
 
Operating Income (+$)
Gross Profit88,856
Operating Expense-465,600
Operating Income-376,744-376,744
 
Operating Expense (+$)
Research Development237,729
Selling General Administrative265,542
Selling And Marketing Expenses37,671
Operating Expense465,600540,942
 
Net Interest Income (+$)
Interest Income21,768
Interest Expense-11,334
Other Finance Cost-0
Net Interest Income10,434
 
Pretax Income (+$)
Operating Income-376,744
Net Interest Income10,434
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-376,110-377,378
EBIT - interestExpense = -388,078
-111,176
-100,065
Interest Expense11,334
Earnings Before Interest and Taxes (EBIT)-376,744-364,776
Earnings Before Interest and Taxes (EBITDA)-331,812
 
After tax Income (+$)
Income Before Tax-376,110
Tax Provision-223
Net Income From Continuing Ops-376,333-376,333
Net Income-111,399
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses521,982
Total Other Income/Expenses Net634-10,434
 

Technical Analysis of Travere
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Travere. The general trend of Travere is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Travere's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Travere Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 7.11 < 8.41 < 8.99.

The bearish price targets are: 5.57 > 5.25.

Tweet this
Travere Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Travere Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Travere Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Travere Therapeutics Inc. The current macd is -0.45451561.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Travere price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Travere. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Travere price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Travere Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartTravere Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Travere Therapeutics Inc. The current adx is 29.33.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Travere shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Travere Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Travere Therapeutics Inc. The current sar is 7.0356245.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Travere Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Travere Therapeutics Inc. The current rsi is 26.68. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Travere Therapeutics Inc Daily Relative Strength Index (RSI) ChartTravere Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Travere Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Travere price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Travere Therapeutics Inc Daily Stochastic Oscillator ChartTravere Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Travere Therapeutics Inc. The current cci is -137.86419954.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Travere Therapeutics Inc Daily Commodity Channel Index (CCI) ChartTravere Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Travere Therapeutics Inc. The current cmo is -64.93873859.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Travere Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartTravere Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Travere Therapeutics Inc. The current willr is -97.54901961.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Travere Therapeutics Inc Daily Williams %R ChartTravere Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Travere Therapeutics Inc.

Travere Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Travere Therapeutics Inc. The current atr is 0.42187097.

Travere Therapeutics Inc Daily Average True Range (ATR) ChartTravere Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Travere Therapeutics Inc. The current obv is 419,892.

Travere Therapeutics Inc Daily On-Balance Volume (OBV) ChartTravere Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Travere Therapeutics Inc. The current mfi is 25.36.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Travere Therapeutics Inc Daily Money Flow Index (MFI) ChartTravere Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Travere Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Travere Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Travere Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.683
Ma 20Greater thanMa 507.085
Ma 50Greater thanMa 1007.695
Ma 100Greater thanMa 2008.074
OpenGreater thanClose6.240
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Travere with someone you think should read this too:
  • Are you bullish or bearish on Travere? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Travere? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Travere Therapeutics Inc

I send you an email if I find something interesting about Travere Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Travere Therapeutics Inc.

Receive notifications about Travere Therapeutics Inc in your mailbox!